SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc.
(Nasdaq: SGXP) announced today that it has entered into a license and
collaboration agreement with Novartis focused on the development and
commercialization of BCR-ABL inhibitors for the treatment of drug resistant
Chronic Myelogenous Leukemia (CML).
--
Posted by Rob to CML Newswire: Medical And Technical News On Chronic Myelogenous Leukemia at 3/28/2006 01:14:44 AM
--
Powered by NewOrleansEmail.Com http://neworleansemail.com
--~--~---------~--~----~------------~-------~--~----~
[CMLHope]
A support group of http://cmlhope.com
-------------------------------------------------
You received this message because you are subscribed to the Google Groups "CMLHope" group.
To post to this group, send email to [email protected]
To unsubscribe from this group, send email to [EMAIL PROTECTED]
For more options, visit this group at http://groups.google.com/group/CMLHope
-~----------~----~----~----~------~----~------~--~---
